Lacosamide Oral Solution
Product Images NDC 82983-427

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lacosamide Oral Solution (NDC 82983-427). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajenat Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Label)

Label for Lacosamide Oral Solution USP 10 mg/mL, a 200 mL oral solution by Ajenat Pharmaceuticals LLC. The label includes the NDC 82983-427-31, storage instructions, a barcode, and a pharmacist warning to dispense the medication guide to each patient. The label also specifies the solution is for prescription use only.*

FDA Label Image

Lacofig1 (Laco Fig 1)

A bar chart titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' displaying seizure reduction percentages for placebo and lacosamide doses across three studies. Each study shows bars for placebo and lacosamide at 200, 400, and 600 mg/day doses with seizure reduction percentages labeled, indicating higher reductions for lacosamide compared to placebo.*

FDA Label Image

Lacofig2a (Laco Fig 2a)

A line graph titled 'Proportion of Patients by Responder Rate for Lacosamide Oral Solution and Placebo Groups in Studies 2, 3, and 4.' The x-axis shows Percent of Patients from 0 to 100, and the y-axis shows Responder Rate (equal to or greater) from -100% to 100%, with labels indicating improvement and worsening. Four lines represent Placebo, Lacosamide 200 mg/day, Lacosamide 400 mg/day, and Lacosamide 600 mg/day, each showing the relationship between percent of patients and responder rate.*

FDA Label Image

Lacostructure (Laco Structur)

Chemical structure of lacosamide, showing its molecular framework with acetyl, amino, and benzyl groups.*

FDA Label Image

Lacofig3 (Lacofig3)

A Kaplan-Meier survival curve comparing the proportion of patients over time (days) between two groups: Lacosamide (N=116) and Placebo (N=121). The graph includes statistical annotations with a p-value of 0.001, a hazard ratio (HR) of 0.648 indicating a 35.2% risk reduction, and a 95% confidence interval [0.381, 0.788]. The x-axis represents time in days, and the y-axis represents the proportion of patients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.